دورية أكاديمية
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
| العنوان: | Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. |
|---|---|
| المؤلفون: | Ludwig, Heinz, Terpos, Evangelos, van de Donk, Niels, Mateos, Maria-Victoria, Moreau, Philippe, Dimopoulos, Melitios-Athanasios, Delforge, Michel, Rodriguez-Otero, Paula, San-Miguel, Jesús, Yong, Kwee, Gay, Francesca, Einsele, Hermann, Mina, Roberto, Caers, Jo, Driessen, Christoph, Musto, Pellegrino, Zweegman, Sonja, Engelhardt, Monika, Cook, Gordon, Weisel, Katja, Broijl, Annemiek, Beksac, Meral, Bila, Jelena, Schjesvold, Fredrik, Cavo, Michele, Hajek, Roman, Touzeau, Cyrille, Boccadoro, Mario, Sonneveld, Pieter |
| المصدر: | The Lancet Oncology, 24 (6), e255 - e269 (2023-06) |
| بيانات النشر: | Elsevier Ltd, 2023. |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | cell-associated neurotoxicity, Antibodies, Bispecific, Interleukin 1 Receptor Antagonist Protein, Humans, Cytokine Release Syndrome/etiology, Cytokine Release Syndrome/prevention & control, Cytokine Release Syndrome/drug therapy, Interleukin 1 Receptor Antagonist Protein/therapeutic use, Consensus, Immunotherapy, Adoptive/adverse effects, T-Lymphocytes, Multiple Myeloma/drug therapy, Antibodies, Bispecific/adverse effects, Cytokine Release Syndrome, Immunotherapy, Adoptive, Multiple Myeloma, Oncology, Human health sciences, Hematology, Sciences de la santé humaine, Hématologie |
| الوصف: | T-cell redirecting bispecific antibodies (BsAbs) and chimeric antigen receptor T cells (CAR T cells) have revolutionised multiple myeloma therapy, but adverse events such as cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, hypogammaglobulinaemia, and infections are common. This Policy Review presents a consensus from the European Myeloma Network on the prevention and management of these adverse events. Recommended measures include premedication, frequent assessing for symptoms and severity of cytokine release syndrome, step-up dosing for several BsAbs and some CAR T-cell therapies; corticosteroids; and tocilizumab in the case of cytokine release syndrome. Other anti-IL-6 drugs, high-dose corticosteroids, and anakinra might be considered in refractory cases. ICANS often arises concomitantly with cytokine release syndrome. Glucocorticosteroids in increasing doses are recommended if needed, as well as anakinra if the response is inadequate, and anticonvulsants if convulsions occur. Preventive measures against infections include antiviral and antibacterial drugs and administration of immunoglobulins. Treatment of infections and other complications is also addressed. |
| نوع الوثيقة: | journal article http://purl.org/coar/resource_type/c_6501Test article peer reviewed |
| اللغة: | English |
| العلاقة: | https://api.elsevier.com/content/article/PII:S1470204523001596?httpAccept=text/xmlTest; urn:issn:1470-2045; urn:issn:1474-5488 |
| DOI: | 10.1016/S1470-2045(23)00159-6 |
| الوصول الحر: | https://orbi.uliege.be/handle/2268/310482Test |
| حقوق: | open access http://purl.org/coar/access_right/c_abf2Test info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsorb.310482 |
| قاعدة البيانات: | ORBi |
| DOI: | 10.1016/S1470-2045(23)00159-6 |
|---|